DNA and immune system cells

The term DNA and immune system cells does not refer to a single, specific therapeutic target but rather describes a broad biological domain involving genetic material and various cellular components of the immune system. In pharmacology, a target is typically a discrete molecular entity, such as a protein or a specific nucleic acid sequence, that interacts with a drug to produce a therapeutic effect (Nature Reviews Drug Discovery, 2006). While DNA itself can be a target for certain chemotherapeutic agents like alkylating agents, and immune cells are the site of action for many immunotherapies, the combination of these terms is too non-specific for standard target classification. Specific targets within this context might include Toll-like receptor 9 (TLR9), which senses unmethylated CpG DNA in immune cells, or the cyclic GMP-AMP synthase (cGAS)-STING pathway, which mediates immune responses to cytosolic DNA (Hopfner & Hornung, Nature Reviews Immunology, 2020). Because this entry describes a general area of study or a system rather than a distinct druggable molecule, it is classified as an incorrect target designation for structured pharmacological data (Pommier et al., Chemical Reviews, 2016).

Not applicable as this is a broad biological category rather than a specific molecular target.